Madeleine Pharmaceuticals, Inc. is a U.S. biotechnology company seeking to develop MP3167 (Vastiras®) as protein replacement therapy for the treatment of cardiorenal complications associated with acute (AHF) and chronic (CHF) heart failure. Vastiras® can be formulated for both in-patient and out-patient care. Madeleine Pharmaceuticals, Inc. has unencumbered access to the IP in Madeleine Pty Ltd., the original company formed in 2009 in Australia after being spun out of a leading biomedical company Hospira (former NYSE:HSP), now wholly owned by Pfizer Pharmaceuticals, Inc. (NYSE:PFE) by acquisition in 2015. Madeleine Pty Ltd. maintains an Australian presence for Madeleine Pharmaceuticals, Inc. with access to regional grants, research expertise and Asian markets among other benefits.
